MYOZYME

Երկիր: Ինդոնեզիա

Լեզու: ինդոնեզերեն

Աղբյուրը: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency

Ակտիվ բաղադրիչ:

ALGLUCOSIDASE ALFA

Հասանելի է:

AVENTIS PHARMA - Indonesia

INN (Միջազգային անվանումը):

ALGLUCOSIDASE ALFA

Դոզան:

50 Mg

Դեղագործական ձեւ:

SERBUK INFUS

Միավորները փաթեթում:

DUS, 1 VIAL @ 50 MG

Պատրաստված է:

GENZYME IRELAND LIMITED - Ireland

Հաստատման ամսաթիվը:

2020-10-29

Ապրանքի հատկությունները

Pharmacode
1. NAME OF THE MEDICINAL PRODUCT
Myozyme 50 mg powder for concentrate for solution for infusion
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
One vial contains 50 mg of alglucosidase alfa.
After reconstitution, the solution contains 5 mg of alglucosidase
alfa* per ml
and after dilution, the concentration varies from 0.5 mg to 4 mg/ml.
*Human acid α-glucosidase is produced in Chinese hamster ovary cells
(CHO)
by recombinant DNA technology.
For the full list of excipients, see section 6.1.
3. PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion.
White to off-white powder.
4. CLINICAL PARTICULARS
4.1 THERAPEUTIC INDICATIONS
Myozyme is indicated for long-term enzyme replacement therapy (ERT) in
patients with a confirmed diagnosis of Pompe disease (acid
α-glucosidase
deficiency).
Myozyme is indicated in adults and paediatric patients of all ages.
4.2 POSOLOGY AND METHOD OF ADMINISTRATION
Myozyme treatment should be supervised by a physician experienced in
the
management of patients with Pompe disease or other inherited metabolic
or
neuromuscular diseases.
Posology
The recommended dose regimen of alglucosidase alfa is 20 mg/kg of body
weight administered once every 2 weeks.
Patient response to treatment should be routinely evaluated based on a
comprehensive evaluation of all clinical manifestations of the
disease.
Paediatric and older people
There
is
no
evidence
for
special
considerations
when
Myozyme
is
administered to paediatric patients of all ages or older people.
Patients with renal and hepatic impairment
The safety and efficacy of Myozyme in patients with renal or hepatic
impairment have not been evaluated and no specific dose regimen can be
recommended for these patients.
Method of Administration
Myozyme should be administered as an intravenous infusion.
Infusions should be administered incrementally. It is recommended that
the
infusion begin at an initial rate of 1 mg/kg/h and be gradually
increased by 2
mg/kg/h every 30 minutes if there are no signs of infusion associated
reactions (